Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
斯科特·普萊沙被任命爲首席執行官，Ligand Pharmicals宣佈推出Pelthos Therapeutics以加速ZELSUVMI的商業化
Pharmaceutical executive Scott Plesha named CEO
製藥業高管斯科特·普萊沙被任命爲首席執行官
Lead product ZELSUVMI expected to be commercially available in late 2024
主要產品 ZELSUVMI 預計將於 2024 年底上市
Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
Ligand Pharmicals（納斯達克股票代碼：LGND）今天宣佈成立生物製藥公司Pelthos Therapeutics（Pelthos），並任命經驗豐富的行業高管斯科特·普萊沙爲首席執行官。
This press release features multimedia. View the full release here:
本新聞稿以多媒體爲特色。在此處查看完整版本：
Scott Plesha, CEO, Pelthos Therapeutics (Photo: Business Wire)
Pelthos Therapeutics首席執行官斯科特·普萊沙（照片：美國商業資訊）
Pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of...
Pelthos 致力於將創新、安全和有效的治療產品商業化，以幫助受疾病...
登入免費觀看全文
登入/註冊